Petrie JR, Guzik TJ, Touyz RM
#Biotech #Pharma #GLP1 #ObesityCare #EliLilly #NovoNordisk #KIRIAAdvisoryPartners #KIRIA This is where differentiation becomes less about molecule innovation and more about patient experience design
April 11, 2024: Wegovy Lawsuit Strategy: Novo Nordisk Files Statement of the Case Wegovy manufacturer Novo Nordisk filed a statement of the case on April 9, 2024
Traveling with tirzepatide requires planning, especially for keeping the medication properly stored during transit
For example, Mounjaro contains the active ingredient tirzepatide, a dual agonist that acts on GLP-1 and GIP
Although the inhibition of CA9 did not affect the basal level of glycolysis, it significantly inhibited the gemcitabine-induced acceleration of extracellular acidification and mitochondrial functions in cancer cells, which was verified in xenografted mice